Page last updated: 2024-08-22

camptothecin and lurtotecan

camptothecin has been researched along with lurtotecan in 34 studies

Research

Studies (34)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	15 (44.12)	18.2507
2000's	19 (55.88)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fan, Y; Kohn, KW; Pommier, Y; Shi, LM; Weinstein, JN	1
St Claire, RL; Stafford, CG	1
Besterman, JM; Brown, HR; Emerson, DL; Evans, MG; Leitner, PP; Luzzio, MJ; Shaffer, JE; Sternbach, DD; Uehling, D; Vuong, A	1
Creemers, GJ; de Boer-Dennert, M; Gerrits, CJ; Harteveld, M; Kunka, R; Marijnen, Y; Planting, AS; Schellens, JH; Selinger, K; Verweij, J; Wissel, P	1
Aureche, C; Depee, S; Selinger, K; Smith, G	1
Besterman, JM	1
Burke, TG; Warner, DL	1
Creemers, GJ; de Boer-Dennert, M; DePee, S; Gerrits, CJ; Harteveld, M; Planting, AS; Pritchard, JF; Schellens, JH; Verweij, J; Wissel, P	1
de Jonge, MJ; Gerrits, CJ; Schellens, JH; Stoter, G; Verweij, J	1
Baker, SD; Burke, TG; Burris, HA; DePee, S; Eckardt, JR; Eckhardt, SG; Fields, S; Kuhn, JG; Kunka, R; Littlefield, D; Rodriguez, G; Rothenberg, ML; Rowinsky, EK; Smith, L; Thurman, A; Von Hoff, DD; Warner, DL; White, L; Wissel, P	1
Brown, R; McDonald, AC	1
Alden, M; Beranek, P; Cassidy, J; DeMaria, D; Depee, S; Kaye, S; Kunka, R; Littlefield, D; O'Dwyer, P; Paz-Ares, L; Reilly, D; Twelves, C; Wissel, P	1
Amantea, M; Colbern, GT; Dykes, DJ; Engbers, C; Hiller, A; Luzzio, M; Musterer, R; Pegg, E; Saville, R; Uster, P; Weng, S; Working, PK	1
Bigg, DC; Lavergne, O	1
DeMaria, D; Grochow, LB; Kaye, SB; McDonald, A; O'Dwyer, PJ; Paz-Ares, L; Selinger, K; Sludden, J; Stevenson, JP; Twelves, C; Wissel, P	1
Dombernowsky, P; Drings, P; Hanauske, AR; Morant, R; Nielsen, D; Roelvink, M; Sessa, C; Wanders, J; Wissel, P	1
Brouwer, E; de Bruijn, P; Gill, S; Hamilton, M; Kehrer, D; Loos, WJ; Nooter, K; Sparreboom, A; Stoter, G; Verweij, J	1
de Bruijn, P; Loos, WJ; Sparreboom, A; Verweij, J	1
Baccanari, D; Bendele, R; Brown, E; Chiang, S; Desjardins, JP; Dihel, LC; Emerson, DL; Gill, SC; Hamilton, M; LeRay, JD; Luzzio, MJ; Moon-McDermott, L; Moynihan, K; Richardson, FC; Tomkinson, B	1
Gamucci, T; Hanauske, A; Heinrich, B; Kaye, S; Paridaens, R; Pavlidis, N; Roelvink, M; Schellens, JH; Sessa, C; Verweij, J; Wanders, J	1
Abbott, EA; Bendele, RA; Brown, EN; Desjardins, JP; Dihel, L; Emerson, DL; Hamilton, M; Leray, JD; Ptaszynski, M; Richardson, FC; Tomkinson, BE	1
Gatto, B; Moro, S; Palumbo, M; Sissi, C; Zagotto, G	1
Bos, AM; Cameron, T; de Jonge, MJ; de Vries, EG; Groen, HJ; Hamilton, M; Kehrer, DF; Loos, WJ; Sparreboom, A; Verweij, J	1
de Bruijn, P; de Groot, FM; Hamilton, M; Kehrer, DF; Loos, WJ; Nooter, K; Sparreboom, A; Stoter, G; Verweij, J	1
Calvert, H; Cortes-Funes, H; Dombernowsky, P; Gamucci, T; Gore, ME; Hanauske, AR; Heinrich, B; Kaye, SB; Lehnert, M; Loos, WJ; Paridaens, R; Pavlidis, N; Roelvink, M; Schellens, JH; Selinger, K; Sessa, C; van Oosterom, AT; Verweij, J; Wanders, J; Wissel, PS	1
Bailly, C; Lansiaux, A	1
Bendele, R; Brown, E; Emerson, DL; Giles, FJ; Gray, A; Hart, K; LeRay, JD; Meyer, D; Pelanne, M; Tomkinson, B	1
Eisenhauer, E; Fisher, B; Gelmon, K; Hirte, HW; MacKenzie, MJ; Ptaszynski, M; Siu, LL	1
Albitar, M; Barrett, E; Cortes, JE; Garcia-Manero, G; Giles, FJ; Hamilton, M; Kantarjian, HM; Tallman, MS; Thomas, DA; Verstovsek, S; Wierda, WG	1
Astrow, A; Barrett, E; Campos, S; Matulonis, U; Muggia, F; Roche, M; Rusk, J; Seiden, MV; Sivret, J	1
Eisenhauer, E; Fisher, B; Gelmon, K; Hamilton, M; Hirte, H; Onetto, N; Ptaszynski, M; Walsh, W	1
Baron, B; Bloch, J; Borner, M; Chollet, P; Degardin, M; Dittrich, C; Duffaud, F; Fumoleau, P; Lacombe, D; Rolland, F; Vermorken, JB	1
Barrett, E; Calvert, AH; Cameron, T; Coleman, R; Dark, GG; Eisenhauer, EA; Ellard, S; Grimshaw, R; Hamilton, M; Jayson, G; Kaye, S; Le, T; McIntosh, L; Poole, C; Swenerton, K; Trudeau, M; Vasey, P; Walsh, W	1
Takimoto, CH	1

Reviews

5 review(s) available for camptothecin and lurtotecan

Article	Year
Topoisomerase I inhibition by the camptothecin analog Gl147211C. From the laboratory to the clinic. Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; Humans; Mice; Topoisomerase I Inhibitors	1996
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. British journal of cancer, 1997, Volume: 76, Issue:7 Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Topoisomerase I Inhibitors; Topotecan	1997
[The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan]. Bulletin du cancer, 1998, Volume: Spec No Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Macromolecular Substances; Mice; Molecular Structure; Neoplasm Proteins; Prodrugs; Structure-Activity Relationship; Topoisomerase I Inhibitors	1998
Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography. Anti-cancer drugs, 2000, Volume: 11, Issue:5 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan	2000
Quantitation of camptothecin and related compounds. Journal of chromatography. B, Biomedical sciences and applications, 2001, Nov-25, Volume: 764, Issue:1-2 Topics: Camptothecin; Enzyme Inhibitors; Humans; Irinotecan; Topoisomerase I Inhibitors; Topotecan	2001

Trials

16 trial(s) available for camptothecin and lurtotecan

Article	Year
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration. British journal of cancer, 1996, Volume: 73, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topoisomerase I Inhibitors	1996
Determination of GI147211 in human blood by HPLC with fluorescence detection. Journal of pharmaceutical and biomedical analysis, 1995, Volume: 13, Issue:12 Topics: Antineoplastic Agents; Biotransformation; Calibration; Camptothecin; Chromatography, High Pressure Liquid; Drug Stability; Half-Life; Humans; Hydrolysis; Infusions, Intravenous; Neoplasms; Reference Standards; Spectrometry, Fluorescence	1995
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor. British journal of cancer, 1997, Volume: 76, Issue:7 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Camptothecin; Fatigue; Female; Humans; Injections, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Stomatitis; Thrombocytopenia; Topoisomerase I Inhibitors; Treatment Outcome; Vomiting	1997
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks. Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia	1998
A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion. British journal of cancer, 1998, Volume: 78, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Time Factors; Topoisomerase I Inhibitors	1998
Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion. Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Treatment Outcome	1999
Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: a study of the EORTC Early Clinical Studies Group (ECSG). Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Prognosis; Salvage Therapy; Survival Rate; Treatment Outcome	2000
Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study. Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Treatment Outcome	2000
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-01, Volume: 20, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Thrombocytopenia	2002
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies. Investigational new drugs, 2002, Volume: 20, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Sampling Studies; Topoisomerase I Inhibitors	2002
A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Treatment Outcome	2004
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer, 2004, Apr-01, Volume: 100, Issue:7 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid; Male; Metabolic Clearance Rate; Middle Aged; Mouth Mucosa; Topoisomerase I Inhibitors; Treatment Outcome	2004
A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecologic oncology, 2004, Volume: 93, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Carriers; Drug Resistance, Neoplasm; Female; Humans; Liposomes; Middle Aged; Ovarian Neoplasms; Topotecan	2004
A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers. Investigational new drugs, 2004, Volume: 22, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Time Factors	2004
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study. European journal of cancer (Oxford, England : 1990), 2004, Volume: 40, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis	2004
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Mar-20, Volume: 23, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Canada; Drug Administration Schedule; Endpoint Determination; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms	2005

Other Studies

13 other study(ies) available for camptothecin and lurtotecan

Article	Year
Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin. Journal of medicinal chemistry, 1998, Jun-18, Volume: 41, Issue:13 Topics: Amino Acid Substitution; Antineoplastic Agents; Binding Sites; Camptothecin; DNA; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Enzyme Inhibitors; Hydrogen Bonding; Ligands; Models, Molecular; Molecular Conformation; Mutation; Protein Conformation; Stereoisomerism; Structure-Activity Relationship; Thermodynamics; Topoisomerase I Inhibitors	1998
High-performance liquid chromatographic analysis of the lactone and carboxylate forms of a topoisomerase I inhibitor (the antitumor drug GI147211) in plasma. Journal of chromatography. B, Biomedical applications, 1995, Jan-06, Volume: 663, Issue:1 Topics: Animals; Antineoplastic Agents; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Dogs; Drug Stability; Hydrogen-Ion Concentration; Lactones; Sensitivity and Specificity; Topoisomerase I Inhibitors	1995
In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Cancer research, 1995, Feb-01, Volume: 55, Issue:3 Topics: Animals; Antineoplastic Agents; Body Weight; Camptothecin; Cattle; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Nude; Thymus Gland; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured	1995
Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. Journal of chromatography. B, Biomedical sciences and applications, 1997, Mar-28, Volume: 691, Issue:1 Topics: Acetonitriles; Antineoplastic Agents, Phytogenic; Buffers; Camptothecin; Carboxylic Acids; Chromatography, High Pressure Liquid; Ethylamines; Humans; Hydrogen-Ion Concentration; Irinotecan; Lactones; Osmolar Concentration; Topotecan	1997
Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. British journal of cancer, 1998, Volume: 78, Issue:6 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Flow Cytometry; Genes, p53; Humans; Irinotecan; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Protein p53	1998
Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:12 Topics: Animals; Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Drug Carriers; Drug Screening Assays, Antitumor; Enzyme Inhibitors; HT29 Cells; Humans; Liposomes; Male; Mice; Mice, Nude; Neoplasm Transplantation; Rats; Rats, Sprague-Dawley; Topoisomerase I Inhibitors; Transplantation, Heterologous; Treatment Outcome	1998
Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography. Journal of chromatography. B, Biomedical sciences and applications, 2000, Jan-28, Volume: 738, Issue:1 Topics: Acetonitriles; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Humans; Perchlorates; Sensitivity and Specificity	2000
Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:7 Topics: Animals; Antineoplastic Agents; Area Under Curve; Camptothecin; Carbon Radioisotopes; Drug Carriers; Female; Humans; KB Cells; Liposomes; Mice; Mice, Nude; Sarcoma; Tissue Distribution; Topotecan; Xenograft Model Antitumor Assays	2000
Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice. Anti-cancer drugs, 2001, Volume: 12, Issue:3 Topics: Animals; Antineoplastic Agents; Area Under Curve; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Humans; Liposomes; Mice; Mice, Nude; Neoplasms; Tissue Distribution	2001
Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:3 Topics: Adult; Antineoplastic Agents; Camptothecin; Cell Division; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Humans; Light; Male; Middle Aged; Molecular Structure; Tumor Cells, Cultured	2002
[A symphony for the camptothecins]. Bulletin du cancer, 2003, Volume: 90, Issue:3 Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Irinotecan; Music; Neoplasms; Organosilicon Compounds; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan	2003
OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL. Leukemia research, 2003, Volume: 27, Issue:11 Topics: Animals; Antineoplastic Agents; Camptothecin; Disease Models, Animal; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Neoplasm Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Heterologous; Tumor Cells, Cultured	2003
Are there any better camptothecins than the ones we have? Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:10 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Resistance, Neoplasm; Humans; Irinotecan; Pancreatic Neoplasms; Research; Topoisomerase I Inhibitors	2003